Notice of Proposed Sale · 144
Galectin Therapeutics Inc.
GALTNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- GALECTIN THERAPEUTICS INCORPORATED
- Issuer CIK
- 0001133416
- Phone
- 6786203186
- Person for whose account securities are to be sold
- Harold Shlevin
- Relationships to issuer
- Director
- Street
- 4960 Peachtree Industrial Blvd. Ste 240
- City
- Norcross
- State / country code
- GA
- Postal code
- 30071
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| COMMON | 22,268 | 112,211.88 | 65,856,898 | 06/29/2026 | NASDAQ | MERRILL LYNCH |
Broker / market maker — proposed row 1, entry 1
- Name
- MERRILL LYNCH
- Street
- 401 E. LAS OLAS BLVD 9TH FL
- City
- FORT LAUDERDALE
- State / country code
- FL
- Postal code
- 33301
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| COMMON | 01/23/2025 | STOCK OPTION EXERCISE | ISSUER | 22,268 | N | 06/29/2026 | CASH UPON EXERCISE |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| HAROLD SHLEVIN | Common | 06/26/2026 | 7,732 | 38,680 |
Seller — prior-sale row 1, entry 1
- Name
- HAROLD SHLEVIN
- Street
- 4960 Peachtree Industrial Blvd. Ste 240
- City
- Norcross
- State / country code
- GA
- Postal code
- 30071
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 06/29/2026
- Signed
- Harold Shlevin
- Plan adoption dates
- 08/29/2025
Company context
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis and portal hypertension, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.